LIQUIDITY (Details) $ in Thousands		1 Months Ended						12 Months Ended		24 Months Ended
	Apr. 24, 2025 shares	Jun. 30, 2025 USD ($) shares	May 31, 2025 USD ($)	Apr. 30, 2025 USD ($) shares	Jul. 31, 2024 USD ($) shares	Apr. 30, 2024 USD ($)	Jan. 31, 2022 USD ($)	Jun. 30, 2025 USD ($) shares	Jun. 30, 2024 USD ($) shares	Jun. 30, 2025 USD ($) item
Net loss								$ 74,412	$ 68,459
Net cash used in operating activities								69,075	57,368
Accumulated deficit		$ 403,856						403,856	329,444	$ 403,856
Cash and cash equivalents		94,107						94,107	70,396	94,107
Marketable debt securities		73,751						73,751	56,741	73,751
Total liabilities		13,363						13,363	11,734	13,363
Current liabilities		$ 11,912						$ 11,912	$ 9,606	$ 11,912
Private Placement
Number of shares issued | shares								1,300,000	1,500,000
Number of private placements | item										2
Sale of stock received on transaction								$ 4,200	$ 6,000
Private Placement 2024
Number of shares issued | shares					1,500,000
Sale of stock received on transaction					$ 6,000
Private Placement 2025
Number of shares issued | shares		1,295,383
Sale of stock received on transaction		$ 4,200
2025 Underwritten Public Offering
Number of shares issued | shares	20,786,923			24,900,000
Prefunded warrants | shares				6,900,000
Proceeds after underwriting discounts and other offering costs				$ 96,800
XOMA (US) LLC | US Clinical Trial Rz358 (ersodetug) | Xoma License Agreement | Upon Regulatory Approval
Milestone closing payment								25,000
XOMA (US) LLC | Phase 2 Clinical Trial RZ358 (ersodetug) | Xoma License Agreement
Milestone closing payment							$ 2,000
XOMA (US) LLC | Phase 3 Clinical Trial RZ 358 (ersodetug) | Xoma License Agreement
Milestone closing payment			$ 5,000			$ 5,000
XOMA (US) LLC | Phase 3 Clinical Trial RZ 358 (ersodetug) | Xoma License Agreement | Upon Regulatory Approval
Milestone closing payment								$ 25,000